RDHLNasdaq

RedHill Biopharma Ltd.

Healthcare·Oncology·Phase 2·Tel Aviv-Yafo, Israel
OncologyInfectious Disease

RedHill Biopharma Ltd. (RDHL): 2 pipeline candidates · 2 clinical trials. Updated within the last hour.

6.9/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -5.16 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 2/Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider Signal4.3

0 buys · 1 sell (180d)

A transparent, data-derived signal for RedHill Biopharma Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$4.2M

Cash

$2.9M

Quarterly Burn

Runway

Revenue

Pipeline (2 candidates)

DrugPhase
abc294640Phase 2
opaganibPhase 2/Phase 3

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

14

Total value held

$124K

HolderSharesValue
gagnon securities llc88,405$66K
citadel advisors llc20,673$15K
xtx topco ltd15,163$11K
stonex group inc.14,481$11K
two sigma securities, llc13,019$10K
gamma investing llc6,684$5K
rhumbline advisers5,116$4K
federation des caisses desjardins du quebec3,388$3K
your advocates ltd., llp19$14
smartleaf asset management llc5$4

Showing top 10 of 14 institutional holders of RedHill Biopharma Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

2 clinical trials·CEO: Mr. Dror Ben-Asher

Frequently asked questions

How many drug candidates are in RedHill Biopharma Ltd.'s pipeline?

RedHill Biopharma Ltd. (RDHL) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is RedHill Biopharma Ltd.'s lead drug candidate?

RedHill Biopharma Ltd.'s most advanced tracked candidate is abc294640 (Phase 2) for Cholangiocarcinoma.

What is RedHill Biopharma Ltd.'s market capitalization?

RedHill Biopharma Ltd.'s market capitalization is approximately $4.2M.

Who is the CEO of RedHill Biopharma Ltd.?

Mr. Dror Ben-Asher is the chief executive officer of RedHill Biopharma Ltd. (RDHL).

Get the full picture on RedHill Biopharma Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.